معرفی
Michael Seaman, Ph.D., is an Associate Professor of Medicine at Beth Israel Deaconess Medical Center and Harvard Medical School (Harvard University), where he serves as Principal Investigator of the Seaman Laboratory. His research focuses on HIV vaccine development and antibody-mediated immunity, with significant contributions to the HIV Vaccine Trials Network (HVTN) and Collaboration for AIDS Vaccine Development (CAVD).
His academic credentials include:
- B.S. in Microbiology, University of Washington, Seattle (1992)
- Ph.D. in Immunology, University of Texas Southwestern Medical Center, Dallas (2000)
- Research Fellowship in Viral Pathogenesis, Beth Israel Deaconess Medical Center (2004)
Dr. Seaman's work centers on HIV immunology, specializing in broadly neutralizing antibody induction, vaccine design against viral pathogens, and translational research bridging laboratory findings to clinical applications. His laboratory employs structural biology, animal models, and clinical trial data to develop novel vaccine strategies targeting HIV's vulnerabilities, with emphasis on CD4 binding site antibodies and germline-targeting approaches.
Analysis of his 2024 publications reveals a concentrated effort in advancing HIV vaccine candidates through human and non-human primate studies, with key themes including heterologous neutralizing antibody induction, cross-clade neutralization, and combination antibody therapies. His team's work spans preclinical model validation to Phase 1/2a clinical trials, demonstrating translational impact across multiple high-impact journals including Nature, Science, and Cell.
His scientific recognition includes:
- NRSA Predoctoral Trainee (NIH #5 T32 CA09082, 1996-1999)
- NRSA Fellow in AIDS Research (NIH #5 T32 AI07386, 2000-2002)
- Network Citizenship Award (HVTN, 2008)
- Young/Early Career Investigator Award (CAVD, 2012)
Dr. Seaman's research is supported by NIH grants and major collaborations including HVTN and CAVD, with ongoing projects focused on germline-targeting vaccines and antibody therapeutics. His laboratory actively contributes to HIV cure research and next-generation preventive strategies through multidisciplinary approaches involving virology, immunology, and structural biology.
The Seaman Laboratory operates within Harvard Medical School's Center for Virology and Vaccine Research (CVVR), collaborating with investigators across virology, immunology, and clinical research domains. Current initiatives include optimizing polyvalent vaccine regimens, characterizing complex viral escape pathways, and developing dual immunotherapy approaches for HIV remission.
